<SEC-DOCUMENT>0001746473-23-000007.txt : 20230309
<SEC-HEADER>0001746473-23-000007.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309161135
ACCESSION NUMBER:		0001746473-23-000007
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230309
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLIANT THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001746473
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474272481
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39303
		FILM NUMBER:		23719862

	BUSINESS ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-481-6770

	MAIL ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plrx-20230309.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:fac67c63-7651-489b-aaba-44ec6e7e1231,g:c38c3fe0-24d8-4f45-b1ce-4b7f417416fb,d:5110a9aacbd043a2b37c4c96a0d7e75a--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>plrx-20230309</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV80L2ZyYWc6ZTQ0YmZjNTAxZjI4NGJiMDk1YzUxNjk4NzEzZThmMmIvdGFibGU6ZjY2NzNkMWMxMzY2NDQ1NWI0YTJlNDRkZjMzYWRkZDcvdGFibGVyYW5nZTpmNjY3M2QxYzEzNjY0NDU1YjRhMmU0NGRmMzNhZGRkN18wLTEtMS0xLTU2NDYw_ef49f796-b388-4ee8-8c00-524735d1f456">0001746473</ix:nonNumeric><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV80L2ZyYWc6ZTQ0YmZjNTAxZjI4NGJiMDk1YzUxNjk4NzEzZThmMmIvdGFibGU6ZjY2NzNkMWMxMzY2NDQ1NWI0YTJlNDRkZjMzYWRkZDcvdGFibGVyYW5nZTpmNjY3M2QxYzEzNjY0NDU1YjRhMmU0NGRmMzNhZGRkN18xLTEtMS0xLTU2NDYw_569266b7-571d-4616-a486-86fd08f003bc">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="plrx-20230309.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5110a9aacbd043a2b37c4c96a0d7e75a_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQz_8d22b410-2ba2-44fe-b1ae-7531398c071f">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY181NDk3NTU4MTUzNTI_e564fb8c-bd57-4ea7-b0ea-86ac5fbdb9c9">March&#160;9, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQ1_b71e5e4b-ce1f-4f70-a422-bf54ec6a8688">PLIANT THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt;padding-left:269.85pt;padding-right:269.85pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8wLTAtMS0xLTU2NDYw_796d5057-e84e-451b-ac9d-5d56cb7cba01">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8wLTEtMS0xLTU2NDYw_4b928bad-c720-4630-85e2-47ccee800b56">001-39303</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8wLTItMS0xLTU2NDYw_ea479e66-80c9-46cd-b42f-36999644e738">47-4272481</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTAtMS0xLTU2NDYwL3RleHRyZWdpb246ZGJjZDZkMmQ1ZmVmNGZiMGI5ZTQzM2EwNzI1MjE3ZThfNQ_047e2bb8-9179-43c2-93c7-9813d10f1bb1">260 Littlefield Avenue,</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTAtMS0xLTU2NDYwL3RleHRyZWdpb246ZGJjZDZkMmQ1ZmVmNGZiMGI5ZTQzM2EwNzI1MjE3ZThfOA_440e9a57-3304-4067-9e19-24ae9da7eb9e">South San Francisco,</ix:nonNumeric> <ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTAtMS0xLTU2NDYwL3RleHRyZWdpb246ZGJjZDZkMmQ1ZmVmNGZiMGI5ZTQzM2EwNzI1MjE3ZThfMTE_dc6a73c8-1fc8-4cf7-9292-88af836ba7ca">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTItMS0xLTU2NDYw_98bd7657-da65-4574-87a5-cac8fde14bbc">94080</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQ2_d41378cc-18ac-4091-ac2a-444af024f2a4">650</ix:nonNumeric>) <ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQw_7ad88b1d-9c24-458b-9591-827cdffd4a15">481-6770</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV8wLTAtMS0xLTU2NDYw_f0d663a2-d003-40d6-a684-8584876735fd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV8yLTAtMS0xLTU2NDYw_a0c3689a-7d3d-4dd5-a1ba-1ab4e10b1026">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV80LTAtMS0xLTU2NDYw_f9980ef0-d44c-4b75-9870-bc329f7a774f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV82LTAtMS0xLTU2NDYw_fc20597a-2ef0-4486-8754-a2311484baeb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ODYxNjUwYzQ3ZWI5NDM3MmJlMDBjN2E2NWVlODI4ZDkvdGFibGVyYW5nZTo4NjE2NTBjNDdlYjk0MzcyYmUwMGM3YTY1ZWU4MjhkOV8xLTAtMS0xLTU2NDYw_60a58b5e-2db3-4377-aa02-b73ed3e52d24">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ODYxNjUwYzQ3ZWI5NDM3MmJlMDBjN2E2NWVlODI4ZDkvdGFibGVyYW5nZTo4NjE2NTBjNDdlYjk0MzcyYmUwMGM3YTY1ZWU4MjhkOV8xLTItMS0xLTU2NDYw_45a6c268-c9ff-4643-a538-c455072e7c06">PLRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ODYxNjUwYzQ3ZWI5NDM3MmJlMDBjN2E2NWVlODI4ZDkvdGFibGVyYW5nZTo4NjE2NTBjNDdlYjk0MzcyYmUwMGM3YTY1ZWU4MjhkOV8xLTQtMS0xLTU2NDYw_8693b32f-d28f-41f6-8abf-023d9531a6c8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;<ix:nonNumeric contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQx_c533580d-a2c5-4035-bc62-aff46490c3e2">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5110a9aacbd043a2b37c4c96a0d7e75a_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company&#8217;s financial results for the fourth quarter ended December&#160;31, 2022. A copy of this press release is furnished as Exhibit 99.1 to this report.</span></div><div style="margin-top:10pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K including the exhibit furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Exchange Act") or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.</span></div><div id="i5110a9aacbd043a2b37c4c96a0d7e75a_13"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 &#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.&#160;</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2022exhibit991.htm">Press Release issued by the Company dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2022exhibit991.htm">March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2022exhibit991.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2022exhibit991.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2022exhibit991.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a4q2022exhibit991.htm">.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5110a9aacbd043a2b37c4c96a0d7e75a_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PLIANT THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;9, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Keith Cummings</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith Cummings, M.D., MBA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a4q2022exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idd22e67f12f04ae48353ad6b05242be4_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pliant Therapeutics Provides Corporate Update and </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reports Fourth Quarter 2022 Financial Results</font></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.5pt">Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC</font></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.5pt">INTEGRIS-IPF 320 mg dose 24-week data expected in the second quarter of 2023</font></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.5pt">$287.5 million equity financing extends runway into the second half of 2026<br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOUTH SAN FRANCISCO, CA., March&#160;9, 2023 - Pliant Therapeutics, Inc. (Nasdaq&#58; PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter 2022 financial results.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;2022 was a transformative year for Pliant. We delivered positive interim data from our Phase 2a INTEGRIS-IPF trial, strengthened our financial position with our first follow-on financing and continued to advance our clinical- and early-stage portfolio. We are positioned to deliver multiple clinical catalysts in 2023.&#34; said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics. &#34;2023 has already been productive with the release of additional positive data from the INTEGRIS-IPF 320 mg cohort, where bexotegrast displayed a continued favorable safety profile and outperformed all lower dose cohorts on exploratory efficacy endpoints. We look forward to sharing additional clinical data readouts and portfolio milestones throughout the remainder of this year.&#34; </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Quarter and Recent Highlights</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Bexotegrast (PLN-74809) Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">INTEGRIS-IPF Phase 2a clinical data from bexotegrast 320 mg dose group at 12 weeks showed bexotegrast was well tolerated and demonstrated statistically significant forced vital capacity (FVC) increases at all time points in patients with idiopathic pulmonary fibrosis (IPF).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Bexotegrast at 320 mg was well tolerated with no drug-related severe or serious adverse events and showed dose-proportional increases in plasma concentrations, consistent with prior studies. Exploratory efficacy endpoints demonstrated strong treatment effects on FVC, Quantitative Lung Fibrosis (QLF) imaging and biomarkers over 12 weeks. In addition, no bexotegrast-treated patients experienced disease progression as defined by FVC percent predicted (FVCpp) decline of greater than or equal to 10%, a risk factor associated with increased mortality in IPF patients.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">INTEGRIS-IPF Phase 2a trial on track for final 24-week data readout from the bexotegrast 320 mg dose group in the second quarter of 2023.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This randomized, double-blind, placebo-controlled trial is evaluating bexotegrast at a once-daily dose of 320 mg administered for at least six months and up to 48 weeks in approximately 28 patients with IPF. The trial will evaluate primary and secondary endpoints of safety, tolerability and pharmacokinetics. Exploratory efficacy endpoints will include effects on FVC and QLF, as well as serum biomarkers. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">INTEGRIS-PSC enrollment complete with topline Phase 2a data expected in the third quarter of 2023.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This 12-week randomized, dose-ranging, double-blind, placebo-controlled trial is evaluating the safety, tolerability and pharmacokinetics of bexotegrast in primary sclerosing cholangitis (PSC) patients. The trial is also evaluating exploratory efficacy endpoints including fibrosis biomarkers such as PRO-C3 and enhanced liver fibrosis (ELF), changes in alkaline phosphatase (ALP), and liver imaging. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">EMA Orphan Drug designation received for bexotegrast for the treatment of IPF.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> European Medicines Agency&#8217;s (EMA&#8217;s) Orphan Drug designation is designed to encourage the development of new treatments for rare conditions. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The benefits of Orphan Drug designation include trial design assistance, a centralized EU approval process, and 10 years of market exclusivity. Bexotegrast received Orphan Drug designation for the treatment of IPF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the United States Food and Drug Administration (FDA) in 2018. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Early-Stage Development Programs</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">IND open for PLN-101095 for the treatment of solid tumors resistant to immune checkpoint inhibitors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the FDA cleared the company&#8217;s Investigational New Drug (IND) application for PLN-101095, an oral, small molecule, dual selective inhibitor of &#945;v&#946;8 and &#945;v&#946;1 integrins. Initiation of a Phase 1 trial of PLN-101095 in patients with solid tumors that are resistant to immune checkpoint inhibitors is expected in the second quarter of 2023.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Muscular dystrophy program progressing through IND enabling activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> IND submission for this program is expected in 2023.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Closing of underwritten public offering of $287.5 million in common stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company closed a public offering in January 2023, yielding $269.9 million in net proceeds to the Company, which included the underwriter&#8217;s exercise in full of their  option to purchase additional shares. Pliant intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and investments, to develop its ongoing and future preclinical and clinical programs including bexotegrast and PLN-101095, further develop its integrin targeting platform, to fund working capital, operating expenses and capital expenditures, and for other general corporate purposes.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Appointment of Lily Cheung as Chief Human Resources Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ms. Cheung brings over 25 years of Human Resources experience across the technology and biopharmaceutical industries, including more than 15 years of commercial-stage experience.    </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Appointments of Darren Cline and Thomas McCourt to the Company&#8217;s Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr. Cline and Mr. McCourt each bring over 30 years of strategic and operational experience in building commercial organizations. Mr. Cline currently serves as Chief Executive Officer and President of Epygenix Therapeutics. Mr. McCourt currently serves as Chief Executive Officer of Ironwood Pharmaceuticals.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Work has completed under the Novartis collaboration. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-year term of the collaboration, Pliant achieved successful validation of a novel integrin receptor as a potential next generation target for the treatment of fibrotic diseases and is in the process of developing candidates against the target. As part of a broad strategic realignment, Novartis has discontinued clinical development in NASH. As a result, Novartis has terminated development of PLN-1474, an inhibitor of &#945;v&#946;1 targeting NASH-associated advanced liver fibrosis, which they licensed in 2019, and returned global rights to Pliant.  PLN-1474 is a phase 2-ready asset, having shown a favorable safety and pharmacokinetic profile in Phase 1 trials.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">2023 Anticipated Milestones</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">24-week data from the 320 mg dose group of the INTEGRIS-IPF Phase 2a trial in patients with IPF is expected in the second quarter of 2023.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initiation of a Phase 2b trial of bexotegrast in patients with IPF is expected in mid-2023.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initiation of a Phase 1 trial of PLN-101095 in patients with solid tumors resistant to immune checkpoint inhibitors is expected in the second quarter of 2023.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Topline data from the 40, 80 and 160 mg dose groups of the INTEGRIS-PSC Phase 2a trial in patients with PSC is expected in the third quarter of 2023.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fourth Quarter 2022 Financial Results</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $25.1 million, as compared to $18.8 million for the prior-year quarter. The increase was due primarily to employee-related expenses, including stock-based compensation, and higher clinical and manufacturing-related costs. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $14.3 million, as compared to $7.8 million for the prior-year quarter. The increase was due to higher personnel-related and professional services expenses.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss of $35.1 million as compared to $24.5 million for the prior-year quarter due to an increase in operating expenses coupled with a slight decrease in collaboration revenues under the Novartis collaboration during the quarter.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December&#160;31, 2022, the Company had cash, cash equivalents and short-term investments of $331.2&#160;million, and including the net proceeds from the January 2023 public offering, the Company expects to be able to fund operations into the second half of 2026.</font></div><div style="margin-top:10pt"><font style="color:#000d1b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Pliant Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, bexotegrast, is an oral small molecule dual selective inhibitor of &#945;v&#223;6 and &#945;v&#223;1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is currently conducting Phase 2a trials of bexotegrast in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of &#945;v&#223;1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis. In December 2022, Pliant submitted an IND for its third clinical program, PLN-101095, a small molecule dual-selective inhibitor of &#945;v&#946;8 and &#945;v&#946;1 integrins, that is being developed for the treatment of solid tumors. In addition to clinical stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements contained in this press release regarding matters that are not historical facts are &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;intend,&#34; and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding the safety, tolerability, pharmacodynamics and therapeutic potential of bexotegrast&#59; our plans for the future development of bexotegrast and PLN-101095&#59; bexotegrast&#8217;s potential to become a treatment for IPF&#59; the anticipated timing of data from the 320 mg group of the INTEGRIS-IPF Phase 2a trial in patients treated for at least 24 weeks&#59; the timing and design of Pliant&#8217;s Phase 2b clinical trial of bexotegrast&#59; the timing of Pliant&#8217;s Phase 1 trial of PLN-101095&#59; the timing and availability of topline data from the 40, 80 and 160 mg dose groups of the INTEGRIS-PSC Phase 2a trial in patients with PSC&#59; discussions with regulatory authorities&#59; planned INDs in our oncology and muscular dystrophy programs&#59; anticipated progress of our clinical trials and timing of enrollment and data disclosures&#59; the efficacy and safety profile and potential of our product candidates&#59; our intended use of the net proceeds from our common stock offering&#59; the sufficiency of our cash runway to fund operations into the second half of 2026 and the availability of additional term loans under our loan facility. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, our reliance on third parties for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled &#34;Risk Factors&#34; and &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations&#34; in our Annual Report on Form 10-K for the year ended December 31, 2022 which we are filing with the SEC today, available on the SEC's website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor and Media Contact&#58;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Keenan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Investor Relations and Corporate Communications</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pliant Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;pliantrx.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="idd22e67f12f04ae48353ad6b05242be4_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:36.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,965&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,999&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,685&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,572&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(25,114)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18,752)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(96,936)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(77,549)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14,251)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(7,846)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(39,949)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(27,558)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(39,365)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(26,598)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(136,885)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(105,107)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss from operations</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(37,400)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(24,599)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(127,200)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(97,535)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest and other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,657&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">272&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(317)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(791)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(35,060)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(24,531)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(123,321)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(97,263)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss attributable to common stockholders</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(35,060)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(24,531)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(123,321)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(97,263)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss per share attributable to common stockholders&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.72)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2.94)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2.71)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shares used in computing net loss per share attributable to common stockholders&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">48,783,242&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">35,925,697&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">42,015,908&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">35,846,421&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><div id="idd22e67f12f04ae48353ad6b05242be4_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.356%"><tr><td style="width:1.0%"></td><td style="width:66.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">33,685&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">51,665&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">297,502&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">148,931&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,983&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,998&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tax credit receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">83&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">83&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,058&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,764&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">340,311&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">209,441&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,486&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,606&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,422&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,330&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">394&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">350,613&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">221,215&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,580&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,971&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,218&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,868&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued and other liabilities </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,123&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lease liabilities, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,457&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,869&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">23,913&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,831&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lease liabilities, non-current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,429&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,325&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,929&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,271&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">22,156&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">653,707&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414,348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(338,412)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(215,091)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,958)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(201)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,342&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199,059&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">350,613&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,215&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>plrx-20230309.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fac67c63-7651-489b-aaba-44ec6e7e1231,g:c38c3fe0-24d8-4f45-b1ce-4b7f417416fb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plrx="http://www.pliantrx.com/20230309" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pliantrx.com/20230309">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20230309_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20230309_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pliantrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>plrx-20230309_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fac67c63-7651-489b-aaba-44ec6e7e1231,g:c38c3fe0-24d8-4f45-b1ce-4b7f417416fb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_f809727a-6f30-4319-b811-bbf2947c7d22_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bef6bba0-31cb-48c2-aeaa-1f19a85326f2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_39abd47b-d67b-4d41-b65d-b6c8cf530f69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_80179d28-6d15-4448-9016-b6f199102adb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a6c34ec4-f7dd-4b55-956f-3bd76ff8dd83_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e4d2689f-83c1-46a5-90bd-30d09de0f38e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_07733a83-9ce8-42cc-bc1d-f7111c97d7e5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0e1ef2f2-b9b0-4627-87a5-c8e9caa398cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6d671018-d649-40ca-869e-851f21a3d8b4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d3e5bd1e-a778-4a8d-83ea-9ee047084fce_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c1b72252-ff13-4ba0-a03e-462cfcb5e970_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4678206c-d7ac-4dfb-a104-f8112db8500b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c759489f-4dd5-45ec-8191-3ae7b963939c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8f100265-85f2-45dd-8fa8-dc23cafe8609_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_73d4b5e1-c887-4452-811d-bd42b822dc22_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d0237184-98cb-4f1c-bd7a-18dc665958ba_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2e2fad40-8d71-423a-a11b-c9c0392b483b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_da303980-3816-40a8-8ae7-c787d6326269_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_55fa6c86-0d28-473d-9b09-b32ed1a0bac0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_37e2a208-9b91-4f2e-9f69-f35ad4f14e8a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_86235620-4050-431e-875c-7a472d1ad268_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_4d1c3ff5-e60b-45a2-bba4-b9107e09f1b3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>plrx-20230309_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fac67c63-7651-489b-aaba-44ec6e7e1231,g:c38c3fe0-24d8-4f45-b1ce-4b7f417416fb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pliantrx.com/role/Cover" xlink:type="simple" xlink:href="plrx-20230309.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e01b5dbf-92d1-46c1-91c7-192eba31314d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_DocumentType_e01b5dbf-92d1-46c1-91c7-192eba31314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8cf0bcd4-b149-41b9-b4d8-6e0d12100239" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_DocumentPeriodEndDate_8cf0bcd4-b149-41b9-b4d8-6e0d12100239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_55366c12-5d72-4001-95c4-dcbce2a59585" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityRegistrantName_55366c12-5d72-4001-95c4-dcbce2a59585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2e1f8d38-4dbe-4d35-a147-ddac716b225e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2e1f8d38-4dbe-4d35-a147-ddac716b225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f6f71e90-fa78-4024-b875-215c2ffaac01" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityFileNumber_f6f71e90-fa78-4024-b875-215c2ffaac01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1d5dc6da-aefe-459d-8f5b-7c7453cbab96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityTaxIdentificationNumber_1d5dc6da-aefe-459d-8f5b-7c7453cbab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2c097b4e-5a79-48dd-a8d6-22ec46e59811" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityAddressAddressLine1_2c097b4e-5a79-48dd-a8d6-22ec46e59811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0fe3875e-cdc1-4610-a4ff-34b5ea55ee1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityAddressCityOrTown_0fe3875e-cdc1-4610-a4ff-34b5ea55ee1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2fc7e184-e186-4266-9476-4e6c4805bc60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityAddressStateOrProvince_2fc7e184-e186-4266-9476-4e6c4805bc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1d69bc41-997b-4d62-9b94-6a7b4bc01075" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityAddressPostalZipCode_1d69bc41-997b-4d62-9b94-6a7b4bc01075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9cde67a7-013c-454c-b251-d08adfa9eea1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_CityAreaCode_9cde67a7-013c-454c-b251-d08adfa9eea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_de47c123-3151-43d3-80c7-4e0276209249" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_LocalPhoneNumber_de47c123-3151-43d3-80c7-4e0276209249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_43728bf4-12d5-4dd6-9e03-13830203ade7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_WrittenCommunications_43728bf4-12d5-4dd6-9e03-13830203ade7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_758c2ead-0f78-4042-8221-3f337a7b5ec3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_SolicitingMaterial_758c2ead-0f78-4042-8221-3f337a7b5ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e78491a3-401a-44d5-8f93-0b00291ca5fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_PreCommencementTenderOffer_e78491a3-401a-44d5-8f93-0b00291ca5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3dc7b3c8-5fac-4a8e-81e1-ba27bca4d8ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3dc7b3c8-5fac-4a8e-81e1-ba27bca4d8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_13186feb-a401-4f86-b1f3-9235f0576e7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_Security12bTitle_13186feb-a401-4f86-b1f3-9235f0576e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_10f49a38-8e6c-4115-acb4-6c9be8a99591" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_TradingSymbol_10f49a38-8e6c-4115-acb4-6c9be8a99591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3d4e2dd5-3f47-4078-9779-cf32b0f15023" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_SecurityExchangeName_3d4e2dd5-3f47-4078-9779-cf32b0f15023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_40d091cc-6699-499c-9aa6-cacbd560b9b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityEmergingGrowthCompany_40d091cc-6699-499c-9aa6-cacbd560b9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_44eb87cb-bbc7-4571-b831-94058bc2b21e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_EntityCentralIndexKey_44eb87cb-bbc7-4571-b831-94058bc2b21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c69d928a-7886-439e-bfcd-59cb83e2036a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8abece3d-1c09-4fc8-b1c5-57a0f2d7163c" xlink:to="loc_dei_AmendmentFlag_c69d928a-7886-439e-bfcd-59cb83e2036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: C0# 2(  A$! Q$!_\0
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MS&'@E213W1@:)TY0^) FF2T445 PHHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=YKD<,8W6&DCRE/]^0<AO?@TIR44V_Z_K;[RX>]9+^OZW^XZ7PGHB:)HT<9
M,TI,LK=]S<D?F:W:**\B<G.3D^IZ,8J*L@HHHJ2@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *IZG>?8K&24<R8Q&O\ >;L*N5SFH7(N;V20_-;V?5?[TG48]:UI
M0YI&5:IR1\S+^RC:ME(Q)8_:+PMU ;E5_.FE7N09USY]\=D(_BBB/!/YBK'D
M&11;2$EIB9KECP40\J*,M,K7" A[G]U:C',<9ZG'UKNO_7]?U9'FV3_K^O\
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M 'O-%%>=?%WQ7K'A/1K&XT>(O)-,R28[ +F@#T6BOEK_ (7/XW_YXO\ D?\
M"FO\:_&D2%Y(V51U)_\ U4 ?4]%?*D7QP\7S-MB&\^BG/]*F_P"%S^-_^>+_
M )'_  H ^I:*\%^'7Q,\4>(/%T-AJ,;+;M&Q.1WX]J]ZH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHI"0 23@#K0!B>+-?C\/:#<7C$&4+B
M).[-Z5Y)$C.PMIY?6[OG[[E^9%S[CBK_ (Q\0)JOB.:5F)T[2?F"]I)!P1[\
M&L9(VD"V<LF&?_2KU_0)\R+^(XKV,-2]G#7=_P!?A^9QU6Y.YIB5[I0F=DVJ
M-AC_ ,\;;JOTY%2B[+(UW;KAY3]FLD_NQGY9&_/FLP2O=$B,;)M3;RD_Z8V_
MWE/MR,5(;L@M>VZ@YQ:V4?HK?*[?@>:VY?Z_K^K(R9H_:([7,P^>/35V6X_Y
MZW X8_D:<JI'MMI'S!:CS[IN[S?>C&?TK.6XCMCYC?-%I@RN?^6UQ]UOKP:?
MY;*$LY'^6/\ TJ]?U=?F1?Q'%%OZ_K^KLEHOAI+C;!(VV2^;SKMO^><!Y4>W
M(J0732QO=(N+B\80VJ_W(?NN?ZUG>8]RHC'R3ZFW[P_\\[?[R_J*<;S<7NXA
MAI2+:RC]$;Y7;\Z+7_K^O^&1G:S_ *_K_@LT#.L):=,-'8KY5JO_ #TG'#'\
MC5S1=,>_U:WTK.^"W_?7D@_BE!W+^AK&$R6S^;G=!IZXC7M)/]UOT->D^#-(
M;3-&$D_-U<'S)2?T_2L:]3V<+K?^OZ]673I>TG9_U_7Y'1 !5  P!T%+117C
MGJ!1110!D^)O^1;OO^N1KY'^'T,4_P 0K..:-9$,_*L,@_-7UQXF_P"1;OO^
MN1KY*^'/_)1K+_KX_P#9J /KK^P-(_Z!MK_WZ%)_PC^C_P#0-M?^_0K2HH X
M3QG\,]!\0Z/.L=E#;7*J622)0O/OBOGGP!JEYX.^(T%JS,H:<03+GC!(KZ_D
M_P!4_P#NFOC?Q8Y@^+5\Z<%+T$?D* /LA'$D:NO1AD4ZJ6D.7T:Q<]6@0G\A
M5V@#XI\1_P#)1;C_ *_O_:E?9MA_QX0?[@KXR\1_\E%N/^O[_P!J5]FV'_'A
M!_N"@"S1110 4444 >7?'C_DGTW^^O\ .O/_ -G/_D8+[_K@?YBO0/CQ_P D
M^F_WU_G7G_[.?_(P7W_7 _S% 'TC1110 5'/,EO \TAPB#)-25P_Q9UL:+X
MU$K)LFN(S'$PZAJ /G&0W'CGXI\@%GN0"",Y1&_PJQ\3-'/@[XA/+8CR@S>?
M%Z+S70_ #1?[1\6W&K2?-]E4@Y[E@:Z7]HK1 UG8ZPB$N'\IB!T&": /8?#&
MIIJ_ARQO(V#!HE!(]0!FM>O(O@!KBWWA!],+9>S;N?[Q)KUV@ I#T-+2'H:
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M_P!=X_Z5])7?ANV\5?#F#3+A1F2U 1R/NGU%?-OQ%_Y*K<_]=X_Z5]7^&_\
MD6]/_P"N"T ?+'@S7+_X:>/S:W<;I"TOE2QD\8)P&_ <U]:VMS%>6L=Q X>*
M1=RL.XKQ'X\^!C<6B>)+"$F6(A9U0<MGO^ %6_@3XZ&IZ:WA^]E/VFV7,18]
M5Z "@#T+X@_\B3J7_7%OY&OG;X%?\CY']!7T3\0?^1)U+_KBW\C7SM\"O^1\
MC^@H ^L**** "O/_ (S?\DVU/_KG_45Z!7G_ ,9O^2;:G_US_J* /(OV>?\
MD<9O^N+_ ,A7T[7S%^SS_P CC-_UQ?\ D*^G: "BBB@ HHHH **** "BBB@
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M?^S5]?ZK9G4-+N+53@RH5!KQKPQ\$+W0_$UOJDEZK+')O*@CUSZ4 >XT444
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M%7ART\4Z!<:9=H&5QE"?X6'0UYO\/_@_>>#_ !(-1EO!)&N, $9- 'L5%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ JJ^GVSZE'J#1@W,<9C5^X4]15JB@"M=V-O>J@N(PX0Y&:;>:;:
MWXA%Q$'\EQ(F>S#H:MT4 9FI^'].U>6.2\AWO']U@<$4[3=#LM)9S:HP+]=S
M9K1HH J66F6FGV\D%M$$CD=G90.I;K42Z)8+9268@ MY/O1]ORK0HH KR65O
M)9BT>-3 %"A,< #I4,FD64L-K%)$&6V</%GG:1T-7J* "LC4?#>F:I=K=74)
M,RKM#J<''I6O10!0T[1[/2T=+5&"OU#-FJ-SX0T:ZN7GDML,YRZJ<*WU'>MV
MB@".""*VA6*&-4C48"J,"H8=/MH+J6YCC EE.7;UJU10!5ET^VGOH+R2,&>
M$1MZ9ZU6U/0-.U9U>Z@!D48$B\-CTSUQ6G10!1TW1['28V2S@6/=]YL?,WU/
M>JE]X6TF_N6N);?;(W+&,[=Q]3CK6S10!!9V5O86RV]K"D42]%10!4]%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139915201124544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLIANT THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4272481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">260 Littlefield Avenue,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-6770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001746473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plrx-20230309_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plrx-20230309.xsd" xlink:type="simple"/>
    <context id="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV80L2ZyYWc6ZTQ0YmZjNTAxZjI4NGJiMDk1YzUxNjk4NzEzZThmMmIvdGFibGU6ZjY2NzNkMWMxMzY2NDQ1NWI0YTJlNDRkZjMzYWRkZDcvdGFibGVyYW5nZTpmNjY3M2QxYzEzNjY0NDU1YjRhMmU0NGRmMzNhZGRkN18wLTEtMS0xLTU2NDYw_ef49f796-b388-4ee8-8c00-524735d1f456">0001746473</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV80L2ZyYWc6ZTQ0YmZjNTAxZjI4NGJiMDk1YzUxNjk4NzEzZThmMmIvdGFibGU6ZjY2NzNkMWMxMzY2NDQ1NWI0YTJlNDRkZjMzYWRkZDcvdGFibGVyYW5nZTpmNjY3M2QxYzEzNjY0NDU1YjRhMmU0NGRmMzNhZGRkN18xLTEtMS0xLTU2NDYw_569266b7-571d-4616-a486-86fd08f003bc">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQz_8d22b410-2ba2-44fe-b1ae-7531398c071f">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY181NDk3NTU4MTUzNTI_e564fb8c-bd57-4ea7-b0ea-86ac5fbdb9c9">2023-03-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQ1_b71e5e4b-ce1f-4f70-a422-bf54ec6a8688">PLIANT THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8wLTAtMS0xLTU2NDYw_796d5057-e84e-451b-ac9d-5d56cb7cba01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8wLTEtMS0xLTU2NDYw_4b928bad-c720-4630-85e2-47ccee800b56">001-39303</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8wLTItMS0xLTU2NDYw_ea479e66-80c9-46cd-b42f-36999644e738">47-4272481</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTAtMS0xLTU2NDYwL3RleHRyZWdpb246ZGJjZDZkMmQ1ZmVmNGZiMGI5ZTQzM2EwNzI1MjE3ZThfNQ_047e2bb8-9179-43c2-93c7-9813d10f1bb1">260 Littlefield Avenue,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTAtMS0xLTU2NDYwL3RleHRyZWdpb246ZGJjZDZkMmQ1ZmVmNGZiMGI5ZTQzM2EwNzI1MjE3ZThfOA_440e9a57-3304-4067-9e19-24ae9da7eb9e">South San Francisco,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTAtMS0xLTU2NDYwL3RleHRyZWdpb246ZGJjZDZkMmQ1ZmVmNGZiMGI5ZTQzM2EwNzI1MjE3ZThfMTE_dc6a73c8-1fc8-4cf7-9292-88af836ba7ca">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6MzMwMmI3NmQwNTJiNGJjYjljNTlkMjVjYWYxOTc0YjIvdGFibGVyYW5nZTozMzAyYjc2ZDA1MmI0YmNiOWM1OWQyNWNhZjE5NzRiMl8zLTItMS0xLTU2NDYw_98bd7657-da65-4574-87a5-cac8fde14bbc">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQ2_d41378cc-18ac-4091-ac2a-444af024f2a4">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQw_7ad88b1d-9c24-458b-9591-827cdffd4a15">481-6770</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV8wLTAtMS0xLTU2NDYw_f0d663a2-d003-40d6-a684-8584876735fd">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV8yLTAtMS0xLTU2NDYw_a0c3689a-7d3d-4dd5-a1ba-1ab4e10b1026">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV80LTAtMS0xLTU2NDYw_f9980ef0-d44c-4b75-9870-bc329f7a774f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ZjYyODY5Y2UxYjU1NGRmZDk1OGQ0ZDIyY2QwZjA0NzUvdGFibGVyYW5nZTpmNjI4NjljZTFiNTU0ZGZkOTU4ZDRkMjJjZDBmMDQ3NV82LTAtMS0xLTU2NDYw_fc20597a-2ef0-4486-8754-a2311484baeb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ODYxNjUwYzQ3ZWI5NDM3MmJlMDBjN2E2NWVlODI4ZDkvdGFibGVyYW5nZTo4NjE2NTBjNDdlYjk0MzcyYmUwMGM3YTY1ZWU4MjhkOV8xLTAtMS0xLTU2NDYw_60a58b5e-2db3-4377-aa02-b73ed3e52d24">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ODYxNjUwYzQ3ZWI5NDM3MmJlMDBjN2E2NWVlODI4ZDkvdGFibGVyYW5nZTo4NjE2NTBjNDdlYjk0MzcyYmUwMGM3YTY1ZWU4MjhkOV8xLTItMS0xLTU2NDYw_45a6c268-c9ff-4643-a538-c455072e7c06">PLRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGFibGU6ODYxNjUwYzQ3ZWI5NDM3MmJlMDBjN2E2NWVlODI4ZDkvdGFibGVyYW5nZTo4NjE2NTBjNDdlYjk0MzcyYmUwMGM3YTY1ZWU4MjhkOV8xLTQtMS0xLTU2NDYw_8693b32f-d28f-41f6-8abf-023d9531a6c8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibafbae57abbb407bbb27887715458cc6_D20230309-20230309"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxMTBhOWFhY2JkMDQzYTJiMzdjNGM5NmEwZDdlNzVhL3NlYzo1MTEwYTlhYWNiZDA0M2EyYjM3YzRjOTZhMGQ3ZTc1YV8xL2ZyYWc6MDM5YWRkOWFjNzNkNDBkYmFjYjliYjQwNTZmYTdhY2MvdGV4dHJlZ2lvbjowMzlhZGQ5YWM3M2Q0MGRiYWNiOWJiNDA1NmZhN2FjY18xNDQx_c533580d-a2c5-4035-bc62-aff46490c3e2">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !P@6E6!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M '"!:5:VE_2![0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( '"!:5:97)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ <(%I5CJM
M21Q8!   DQ   !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( '"!:5:?H!OPL0(  .(,   -
M  "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ <(%I5I>*NQS
M$P(   L              ( !=@\  %]R96QS+RYR96QS4$L! A0#%     @
M<(%I5JK$(A8S 0  (@(   \              ( !7Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( '"!:58D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( '"!
M:59ED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plrx-20230309.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plrx-20230309.htm">plrx-20230309.htm</File>
    <File>a4q2022exhibit991.htm</File>
    <File>plrx-20230309.xsd</File>
    <File>plrx-20230309_lab.xml</File>
    <File>plrx-20230309_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plrx-20230309.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plrx-20230309.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plrx-20230309_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plrx-20230309_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plrx-20230309.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plrx",
   "nsuri": "http://www.pliantrx.com/20230309",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20230309.htm",
      "contextRef": "ibafbae57abbb407bbb27887715458cc6_D20230309-20230309",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.pliantrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20230309.htm",
      "contextRef": "ibafbae57abbb407bbb27887715458cc6_D20230309-20230309",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001746473-23-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001746473-23-000007-xbrl.zip
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MD-IB*EQ_@A\]^-Y%2F=(8^ '1/H(T3KA=B#\P.D'8/)A7)%O<[++"$>D]4X
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M:]+'9^<;^//7LG[U^G5]=9NZ6B)--<SKB_6>6KB\9N%I64M1F"MXHO;C3C%
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MYA8(.\]4.,$O-(BY-10YAY>]0%-Z+Y=7!)@("Q)Q40KMB<2C99J<;M2JJ7U
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M"6M\DSW(BX+RT/P*&;[(\P9;DP1[15P_[&[^^7G3"O]235S7>NW6<D?[9"3
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MI "<U!>=YM?W17IY57K(1\'3=XO7BO(HYE$ XBB$ ).$ 4H9!1A+'LE80A3
MEY>O>4!XH*0/$!8$8(5#P""7 +-881AC&"E6.YVGV8_7U0.C2^GIX+)E_>_;
MR5597K^>3F]O;U_=L6+^*B\NI\CW@^G&>K(VO]NQOPUJ:Y@DR;1^]\%TF9H,
MM5LX_?./LW-^)1<4I-FRI!FO!EBFKY?UBV<YIV7-^4%<7JM%]1_8F('J)0 1
M"."KNZ68G+SPO!4=13Z77Z7RJK_?OGYL'3*95A;33%Y6G^P76:2Y."]I49Y1
M)N<:?>VMO+^6;R?+='$]EYO7K@JIS&[G1='P6J%,*I0PJE#^M6VP:0_XSX2W
MW,7Z#.#J<#\]%\9]G'YZ-K@7.C_(XP/>&J8WY-6$>I^)H>;NPU"]H1\?\7--
MB[RD\P&FQ>,P6Y#GU0MG^MEZF,K1GF1:C[-.W5M0Y5TI,R%7V;+AVDO%VXE^
M-A,RG;W/RK2\/]7K7D'G'_4%=_^2]S-%_"1&,061"GR  Y@ 1B $C"F4X)C'
M J%9^3"I9S(#W\XWX]>#'!AA8A%;V:+10B[SFX(_KFZ+N6G)TJM5M;Z1:487
M<GE-UQ=HF%4AL$)^L@+IK5%Z-4Q/XWPS?0S)A<CY\>F9CXR9G#>PS*MR("^>
M1I_SP]$_ZFNI@=>A+R5_=9G_G.IK-04(54] ]:265;O'Z<Z']Z[8X*0%/\#S
MVF+*<UWK7)>@07E5&W8,J,P[?NXKZO2P$R\OA"QT_6H(P3#_+NC=1Z%]IBI=
M56&?;A9,%C,F5<08]74)Q9DN1CD"5%(*H(())6& (F4IZ):11BILC=9KPO56
M>&T%WD9P5Z$_ VW#"-Z>,0?A'V"C1P)H\SQP(C@0X&Y".'2!:V)X)X2>),OU
M'UU=2#@+$LH$CAD0D7[  NL%/@J%?N"$JS#P5938)07#*"--"&N(+S=/O JL
M]SF3M@G!1&S79-"3KF$2@3U3#HE@#Q,]DH#)Z\ )8$]@N^+?9VPO_(N"5LVN
M\_L%R^<SXL,X$8B 2, 08(P)2'P8:;'K$B"!/J*"=15[P_/8!+X&YZW0=9=S
MDZ[#$G8FX<BR[1B_E4B-L3H)L^EI,#$: ]@6H-G =;7]D,[ENC"D$0^PY!BH
M6 B 61B")(P4")B((Z6($"2P6V0?G8]->NL5HP+H6%YO$==U$76C8YBULPL3
M#JOE;L@]%LDM9P.OC;MA["Z)!AM[47XIY&F^6$B-J]KA^;A<WLCBHFJ/%9^5
MTG--8H$BDBA  @X!CJ@6J<\$"'SA)T+Z*B"RJT@/#38VT6J\@&\!]E:(O15D
MK\;<7<8'J3XLZ^<D\,@R[\6=E?"[DN*4" XZ'RPQ= US.U%TOL8^<9SG\Y2G
MI2X,_J!:BRF=S_PX#@)* I!P20!&G /&H=#+.X20)[&(9=@U5>RZ'UMR>$3H
M;2!VSP4&]@ZKOQ\G1]:[#1U6\FZ/VDG0!G>#2;@]E&W1[K'JV>(ZU4\_%Q?Y
M;3;S)90**018PGR]K*,8D%BO[9S(A%,:)(0+IP;7XQAC$^S3IDV%5//H55@=
M6UM;A%HVMMQH&KBMU8DA]Y;6+@?]&UI;/G]-.VLWJ-9FEL'45> ?,YX7UWE1
M]\7/2YTW3O.;K"SN3W,A9Y&(8NA# D2$$X!]3@&)$@E("!6"-!"$83NQ[QUO
MI,)O8'[IU:BKV;U&[E70;?/ ?MZ[YH1G8W.8_-"+2(=TT8F>'JECO_^!TTBG
M8'=32K?+[--+=<OB_,M5GFUZ3R*0(1-0 AK'NLBG1  22 H2*7T<^P0KWKD?
M\-3YV!)'C<^K 5HW[7:(.YP,^M!Q9.5;,&$E\+:0G=2\XVPPZ;:%L:W35IN>
M1?V7?%G2^;_3ZWK)X9#%"(4(* 4#@*O[6J@?R*K"YXJS4":Q[U37-X89FU"?
M%JXKL)Y&Z[2J&YFU+/"=^1JXQN]*E7N9;V2B?Z7?=/MKBGUC:*WUOMG:7O[?
MB[0L959U]FZR];TPRQF.8H+\B ,14PZP4 Q0Z&.@"(1(,!+Z?N==;.,(8Q/]
M&J371-E=ZV8:#\N\-SE'5K@E+U;"WAN[DZ;-'@>3\]Z MI6\W]!>Q-67_W>%
MI*M5.PX37&VR82%"@$/) 8$)! &5,4NB( D2WE6[VX[')MFZH52!LUR6&V0=
M5J@K!4<69L?HK01I"M5)APU'@\G/!'];=<;W'<26_Y3%.[8L"\K++A-HVWY,
M,ZC"Y?UG@^R_SS2'3-&Z3:*&I^%FD2F QC0R&CAL>DI^H]>!>XC815K.Y8PH
MZ/LH"@$)%=*)6PA %"5 <!1PJB2)_,[W"3]U/K;D78/R<N5!]#?V=V\#UV+3
M\RE[AX78AY,C:]&6#KM-SY:XW;8\GSH;;L.S)8S&=F>;C;T\-^?4+_2ELS@0
MF(42 DY(## .D:ZIH !,8,0(0EJBG<_U;#L>FRP?#N=7X+J+L<'582&Z,G!D
M$78+WDIZIDB=9-=P-)CD3/"WY69\WUYJ[[0/4?GY,*>7,^&C((8$@X149^@4
MY%IF,060"!Y%81(21KMJK>%Y;&)[ .=5Z+JKK4G78;DYDW!DO76,WTIPQEB=
M%-?T-)CDC %L:\YLX%Y^OK_C5_I3D9_T)S5#$BDJL ^(B"' **" 0L@ 3[@?
M)(AA$G3N^YD&&)L$-QB]#4BO0FE?A39([%Z)NE)S9&%:LN)4C)I"[U60-AP.
M7I2:PC$5ID8[UTV[K_(RK;Z&9F4][P0-M$B)#P("(X!]_=614!D#'I-81 &*
MD.TYT^8 8Q/O>O?I$:2E>(TD'A9O7VJ.+%Y+5ARVXLRA]]B$>^)PX.TW<SB[
M&V\M=J[B?;^0Q66:7?ZSR&_+J]-\<4VS^UD8*AIQ$@&_.D.*]?=.D# _ 2Q
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M>.#PU>V)[J-['?[PU?\ 4$L! A0#%     @ <(%I5F"F=Z" (   LF(! !4
M             ( !     &$T<3(P,C)E>&AI8FET.3DQ+FAT;5!+ 0(4 Q0
M   ( '"!:58<PD2.$14  *2;   1              "  ;,@  !P;')X+3(P
M,C,P,S Y+FAT;5!+ 0(4 Q0    ( '"!:5:D_V ": (  &X'   1
M      "  ?,U  !P;')X+3(P,C,P,S Y+GAS9%!+ 0(4 Q0    ( '"!:58$
MJ<(A1@H  !A=   5              "  8HX  !P;')X+3(P,C,P,S Y7VQA
M8BYX;6Q02P$"% ,4    " !P@6E6H+=_QJT&  #<,   %0
M@ $#0P  <&QR>"TR,#(S,#,P.5]P<F4N>&UL4$L%!@     %  4 1P$  .-)
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
